ANGO (AngioDynamics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ANGO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Warren Nighan JR | SVP Quality and Regulatory | Sell | — | — |
| 2026-07-24 | Chad Thomas Campbell | SVP/GM, Vascular Access | MIXED | — | — |
| 2026-07-24 | Laura Piccinini | SVP International | MIXED | — | — |
| 2026-07-24 | James C Clemmer | President and CEO | MIXED | — | — |
| 2026-07-24 | Stephen A Trowbridge | EVP and CFO | MIXED | — | — |
| 2026-07-24 | Warren Nighan JR | SVP Quality and Regulatory | MIXED | — | — |
| 2026-07-22 | WESLEY JOHNSON | Director | A | — | — |
| 2026-07-22 | Michael E Tarnoff | Director | A | — | — |
| 2026-07-22 | Stephen A Trowbridge | EVP and CFO | A | — | — |
| 2026-07-22 | Lawrence T Weiss | SVP, Chief Legal Officer | A | — | — |
| 2026-07-22 | Warren Nighan JR | SVP Quality and Regulatory | A | — | — |
| 2026-07-22 | Eileen O'Shea Auen | Director | A | — | — |
| 2026-07-22 | Chad Thomas Campbell | SVP/GM, Vascular Access | A | — | — |
| 2026-07-22 | HOWARD W DONNELLY | Director | A | — | — |
| 2026-07-22 | Lorinda Burgess | Director | A | — | — |
| 2026-07-22 | JAN STERN REED | Director | A | — | — |
| 2026-07-22 | Laura Piccinini | SVP International | A | — | — |
| 2026-07-22 | Karen A Licitra | Director | A | — | — |
| 2026-07-21 | Warren Nighan JR | SVP Quality and Regulatory | F | — | — |
| 2026-07-21 | Lawrence T Weiss | SVP, Chief Legal Officer | F | — | — |
| 2026-07-21 | Chad Thomas Campbell | SVP/GM, Vascular Access | F | — | — |
| 2026-07-21 | Laura Piccinini | SVP International | F | — | — |
| 2026-07-21 | Stephen A Trowbridge | EVP and CFO | F | — | — |
| 2026-07-21 | James C Clemmer | President and CEO | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 862,448 | — |
| — | EVP and CFO | 314,115 | — |
| — | Director | 178,938 | — |
| — | Director | 155,425 | — |
| — | Director | 116,921 | — |
| — | Director | 116,605 | — |
| — | SVP, Chief Legal Officer | 112,618 | — |
| — | SVP/GM, Vascular Access | 108,676 | — |
| — | Director | 102,322 | — |
| — | Director | 95,265 | — |
| — | SVP International | 86,435 | — |
| — | Director | 67,144 | — |
| — | SVP Quality and Regulatory | 64,745 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANGO quote page; the site-wide leaderboard is on the insider transactions hub.